Prevention of hip fractures in osteoporosis

Neuprez, Audrey; Hiligsmann, Mickaël; Bruyère, Olivier; Ethgen, Olivier; Reginster, Jean-Yves

Download

Article (Scientific journals)

Prevention of hip fractures in osteoporosis

Neuprez, Audrey; Hiligsmann, Mickaël; Bruyère, Olivier et al.

2007 • In Minerva Ortopedica e Traumatologica, 58 (5), p. 423-437

Peer reviewed

Permalink
https://hdl.handle.net/2268/24969

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Prevention of hipfractures in osteoporosis.pdf

Publisher postprint (6.28 MB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Osteoporosis; Hip fracture; Prevention; Treatment; Bisphosphonates; Strontium ranelate

Abstract :

[en] Hip fracture is the major clinical consequence of osteoporosis. It is linked with decreased life expectancy and quality of life, placing an ever increasing burden on health services. Few medications have unequivocally demonstrated their ability to reduce hip fracture risk in osteoporotic subjects. Daily alendronate and risedronate reduce hip fracture in patients with low bone mineral density and prevalent vertebral fractures. Intravenous bisphosphonates have been developed, in response to long-term poor adherence to oral anti-osteoporotic treatments. Once-yearly zoledronic acid reduces fracture rates at the spine, non-spine and hip locations. Strontium ranelate, the first drug to uncouple bone formation from bone resorption has also demonstrated its ability to reduce hip fractures in patients above 74 years old, with prevalent low bone mineral density. Calcium and vitamin D supplementation are prerequisite for the management of elderly subjects and should always been associated to anti-resorptive or bone forming agents. Non-pharmacological management of osteoporosis is recommended cannot be considered a substitute for pharmacological treatment of osteoporosis, not even in old age.

Disciplines :

Rheumatology

Author, co-author :

Neuprez, Audrey ; Université de Liège - ULiège > 4e doct. médecine

Hiligsmann, Mickaël ; Université de Liège - ULiège > HEC-Ecole de gestion : UER > Economie industrielle

Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique - Département des sciences de la santé publique

Ethgen, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique : aspects spécifiques

Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique

Language :

English

Title :

Prevention of hip fractures in osteoporosis

Publication date :

2007

Journal title :

Minerva Ortopedica e Traumatologica

ISSN :

0394-3410

eISSN :

1827-1707

Publisher :

Pubblicazione Periodica Mensile

Volume :

Issue :

Pages :

423-437

Peer reviewed :

Peer reviewed

Available on ORBi :

since 04 October 2009

Statistics

Number of views

148 (10 by ULiège)

Number of downloads

138 (7 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Consensus Development Conference. Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993;94:646-50.
Kanis JA, Glüer CC for the Committee of Scientific-Advisors, International Osteoporosis Foundation. An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporos Int 2000;11:192-202.
Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726-33.
Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 2005;36:22-32.
Chevalley T, Guillet E, Herrmann FR, Hoffmeyer P, Rapin CH, Rizzoli R. Incidence of hip fracture over a 10-year period (1991-2000): reversal of a secular trend. Bone 2007;40:1284-9.
Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJ. A population based study of survival after osteoporotic fractures. Am J Epidemiol 1993;137:1001-5.
Zuckerman JD, Skovron ML, Koval KJ, Aharonoff G, Frankel VH. Postoperative complications and mortality associated with operative delay in older patients who have a fracture of the hip. J Bone Joint Surg Am 1995;77:1551-6.
McColl A, Roderick P, Cooper C. Hip fracture incidence and mortality in an English Region: a study using routine National Health Service data. J Public Health Med 1998;20:196-205.
Fisher ES, Baron JA, Malenka DJ, Barrett JA, Kniffin WD, Whaley FS et al. Hip fracture incidence and mortality in New England. Epidemiology 1991;2:116-22.
Bredahl C, Nyholm B, Hindsholm KB, Mortensen JS, Olesen AS. Mortality after hip fracture: results of operation within 12 h of admission. Injury 1992;23:83-6.
Schroder HM, Erlandsen M. Age and sex as determinants of mortality after hip fracture: 3,895 patients followed for 2.5-18.5 years. J Orthop Trauma 1993;7:525-31.
Jensen JS, Tondevold E. Mortality after hip fractures. Acta Orthop Scand 1979;50:161-7.
Stavrou ZP, Erginousakis DA, Loizides AA, Tzevelekos SA, Papagiannakos KJ. Mortality and rehabilitation following hip fracture. A study of 202 elderly patients. Acta Orthop Scand Suppl 1997;275:89-91.
White BL, Fisher WD, Laurin CA. Rate of mortality for elderly patients after fracture of the hip in the 1980's. J Bone Joint Surg Am 1987;69:1335-40.
Wolinsky FD, Fitzgerald JF, Stump TE. The effect of hip fracture on mortality, hospitalization, and functional status: a prospective study. Am J Public Health 1997;87:398-403.
Kreutzfeldt J, Haim M, Bach E. Hip fracture among the elderly in a mixed urban and rural population. Age Ageing 1984;13:111-9.
Forsen L, Sogaard AJ, Meyer HE, Edna T, Kopjar B. Survival after hip fracture: short- and long-term excess mortality according to age and gender. Osteoporos Int 1999;10:73-8.
Boereboom FT, Raymakers JA, Duursma SA. Mortality and causes of death after hip fractures in The Netherlands. Neth J Med 1992;41:4-10.
Elliott J, Beringer T, Kee F, Marsh D, Willis C, Stevenson M. Predicting survival after treatment for fracture of the proximal femur and the effect of delays to surgery. J Clin Epidemiol 2003;56:788-95.
Farahmand BY, Michaelsson K, Ahlbom A, Ljunghall S, Baron JA, Swedish Hip Fracture Study Group. Survival after hip fracture. Osteoporos Int 2005;16:1583-90.
Meyer HE, Tverdal A, Falch JA, Pedersen JI. Factors associated with mortality after hip fracture. Osteoporos Int 2000;11:228-32.
Magaziner J, Lydick E, Hawkes W, Fox KM, Zimmerman SI, Epstein RS et al. Excess mortality attributable to hip fracture in white women aged 70 years and older. Am J Public Health 1997;87:1630-6.
Muraki S, Yamamoto S, Ishibashi H, Nakamura K. Factors associated with mortality following hip fracture in Japan. J Bone Miner Metab 2006;24:100-4.
Richmond J, Aharonoff GB, Zuckerman JD, Koval KJ. Mortality risk after hip fracture. J Orthop Trauma 2003;17:53-6.
Keene GS, Parker MJ, Pryor GA. Mortality and morbidity after hip fractures. BMJ 1993;307:1248-50.
Cornwall R, Gilbert MS, Koval KJ, Strauss E, Siu AL. Functional outcomes and mortality vary among different types of hip fractures: a function of patient characteristics. Clin Orthop Relat Res 2004;425:64-71.
Hannan EL, Magaziner J, Wang JJ, Eastwood EA, Silberzweig SB, Gilbert M et al. Mortality and locomotion 6 months after hospitalization for hip fracture: risk factors and risk-adjusted hospital outcomes. JAMA 2001;285:2736-42.
Kotzan JA, Martin BC, Reeves JH, Wade W. The impact of race and fractures on mortality in a postmenopausal Medicaid population. Clin Ther 1999;21:1988-2000.
Melton LJ 3rd, Therneau TM, Larson DR. Long-term trends in hip fracture prevalence: the influence of hip fracture incidence and survival. Osteoporos Int 1998;8:68-74.
Giversen IM. Time trends of mortality after first hip fractures. Osteoporos Int 2007;18:721-32.
Eiskjaer S, Ostgard SE, Jakobsen BW, Jensen J, Lucht U. Years of potential life lost after hip fracture among postmenopausal women. Acta Orthop Scand 1992;63:293-6.
Parker MJ, Anand JK. What is the true mortality of hip fractures? Public Health 1991;105:443-6.
Drummond MF, O'Brien B, Stoddart GL, Torrance GW, editors. Methods for the economic evaluation of health care programmes, 2nd ed. Oxford: Oxford University Press, 1997.
Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Introduction. Osteoporos Int 1998;8 Suppl 4:S7-80.
Zethraeus N, Borgstrom F, Strom O, Kanis JA, Jonsson B. Cost-effectiveness of the treatment and prevention of osteoporosis-a review of the literature and a reference model. Osteoporos Int 2007;18:9-23.
Tosteson AN, Jonsson B, Grima DT, O'Brien BJ, Black DM, Adachi JD. Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int 2001;12:849-57.
Coons SJ, Rao S, Keininger DL, Hays RD. A comparative review of generic quality-of-life instruments. Pharmacoeconomics 2000;17:13-35.
Tosteson AN, Hammond CS. Quality-of-life assessment in osteoporosis: health-status and preference-based measures. Pharmacoeconomics 2002;20:289-303.
Stevenson M, Loyd Jones LM, De Nigris E, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005;9:1-106.
Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O et al. Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 2006;17:637-50.
Brazier JE, Green C, Kanis JA. A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int 2002;13:768-76.
Gabriel SE, Kneeland TS, Melton LJ 3rd, Moncur MM, Ettinger B, Tosteson AN. Health-related quality of life in economic evaluations for osteoporosis: whose values should we use? Med Decis Making 1999;19:141-8.
Cockerill W, Lunt M, Silman AJ, Cooper C, Ups P, Bhalla AK et al. Health-related quality of life and radiographic vertebral fracture. Osteoporos Int 2004;15:113-9.
Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, De Laet C et al. The risk and burden of vertebral fractures in Sweden. Osteoporos Int 2004;15:20-6.
Oleksik A, Ott SM, Vedi S, Bravenboer N, Compston J, Lips P. Bone structure in patients with low bone mineral density with or without vertebral fractures. J Bone Miner Res 2000;15:1384-92.
Silverman SL, Minshall ME, Shen W, Harper KD, Xie S. The relationship of health-related quality of life to prevalent and incident vertebral fractures in post-menopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis Rheum 2001 44;2611-9.
Tosteson AN, Gabriel SE, Grove MR, Moncur MM, Kneeland TS, Melton LJ 3rd. Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int 2001;12:1042-9.
Zethraeus N, Johnell O, Kanis J, Jonsson B. Cost and quality of life associated with osteoporosis related fractures: results from a Swedish Survey. Stockholm School of Economics; 2002.
Cranney A, Coyle D, Pham BA, Tetroe J, Wells G, Jolly E et al. The psychometric properties of patient preferences in osteoporosis. J Rheumatol 2001;28:132-7.
Salkeld G, Cameron ID, Cumming RG, Easter S, Seymour J, Kurrle SE et al. Quality of life related to fear of falling and hip fracture in older women: a time trade off study. BMJ 2000;320:341-6.
Brazier JE, Kohler B, Walters S. A prospective study of the health related quality of life impact of hip fracture. Sheffield: ScHASR. University of Sheffield; 2000.
Tidermark J, Zethraeus N, Svensson O, Tornkvist H, Ponzer S. Quality of life related to fracture displacement among elderly patients with femoral neck fractures treated with internal fixation. J Orthop Trauma 2002;16:34-8.
Murray C, Brazier JE. Utility following a fracture in a group of elderly women. Qual Life Res 2002,11:642.
Bouee S, Lafuma A, Fagnani F, Meunier PJ, Reginster JY. Estimation of direct unit costs associated with non-vertebral osteoporotic fractures in five European countries. Rheumatol Int 2006,26:1063-72.
Reginster JY, Gillet P, Ben Sedrine W, Brands G, Ethgen O, de Froidmont et al. Direct costs of hip fractures in patients over 60 years of age in Belgium. Pharmacoeconomics 1999;15:507-14.
Autier P, Haentjens P, Bentin J, Baillon JM, Grivegnee AR, Closon MC et al. Costs induced by hip fractures: a prospective controlled study in Belgium. Belgian Hip Fracture Study Group. Osteoporos Int 2000,11:373-80.
Brainsky A, Glick H, Lydick E, Epstein R, Fox KM, Hawkes W et al. The economic cost of hip fractures in community-dwelling older adults: a prospective study. J Am Geriatr Soc 1997;45:281-7.
Zethraeus N, Gerdtham UG. Estimating the costs of hip fracture and potential savings. Int J Technol Assess Health Care 1998;14:255-67.
Jackson RD, LaCroix A, Gass M, Wallace RB, Robbins J, Lewis CE et al. Calcium plus vitamin D supplementation and the risk of fracture. N Engl J Med 2006;354:669-83.
Chapuy MC, Pamphile R, Paris E, Kempf C, Schlichting M, Arnaud S et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int 2002;13:257-64.
Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992;327:1637-42.
Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or old-er. N Engl J Med 1997;337:670-6.
Larsen ER, Mosekilde L, Foldspang A. Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J Bone Miner Res 2004;19:370-8.
Chapuy MC, Arlot ME, Delmas PD, Meunier PJ. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994;308:1081-2.
Lips P, Graafmans WC, Ooms ME, Bezemer PD, Bouter LM. Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med 1996;124:400-6.
Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementations on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003;326:469-74.
Heikinheimo RJ, Inkovaara JA, Harju EJ, Haavisto MV, Kaarela RH, Kataja JM et al. Annual injection of vitamin D and fractures of aged bones. Calcif Tissue Int 1992;51:105-10.
Prince RL, Devine A, Dhaliwal SS, Dick IM. Effects of calcium supplementation on clinical fracture and bone structure. Arch Intern Med 2006;166:869-75.
Shea B, Wells G, Cranney, Zytaruk N, Robinson V, Griffith L et al. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev 2002;23:552-9.
Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P. Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 2007;92:1415-23.
RECORD Trial Group. Oral vitamin D3 and calcium for secondary prevention of law-trauma fractures in elderly people (randomised evaluation of calcium or Vitamin D, record): a randomised placebo-controlled trial. Lancet 2005;365:1621-8.
Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation. JAMA 2005;293:2257-64.
Meyer HE, Smedshaug GB, Kvaavik E, Falch JA, Tverdal A, Pedersen JI. Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomized controlled trial. J Bone Miner Res 2002;17:709-15.
Boonen S, Body JJ, Boutsen Y, Devogelaer JP, Goemaere S, Kaufman JM et al. Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporosis Int 2005;16:239-54.
Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP et al. Ten years experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99.
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA. Reginster JY et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in post-menopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 1999;282:637-45.
Chesnut CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000;109:267-76.
Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD et al. The effects of strontium ranelate on the risk of vertebral fracture in women with post-menopausal osteoporosis. N Engl J Med 2004;350:459-68.
Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-17.
Mastaglia SR, Pellegrini GG, Mandalunis PM, Gonzales Chaves MM, Friedman SM, Zeni SN. Vitamin D insufficiency reduces the protective effect of bisphosphonate on ovariectomy-induced bone loss in rats. Bone 2006;39:837-44.
Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
Cummings SR, Black DM, Thomson DE, Applegate WB, Barrett-Connor E, Musliner TA et al. for the Fracture Intervention Trial Research Group. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures-Results from the Fracture Intervention Trial. JAMA 1998;280:2077-82.
Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA 1999;282:1344-52.
Reginster JY, Minne HW. Sorensen OH, Hooper M, Roux C, Brandi ML et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.Osteoporos Int 2000;11:83-91.
McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C et al. Hip Intervention Program Study Group: Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40.
Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S et al. Fosamax Actonel Comparison Trial Investigators. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteopetrosis: a randomized double-blind study. J Bone Miner Res 2005;20:141-51.
Watts NB, Geusens P, Barton IP, Felsenberg D. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res 2005;20:2097-104.
Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002;87:1586-92.
Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alencironate (REAL) cohort study. Osteoporos Int 2007;18:25-34.
Reginster JY, Rabenda V, Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone 2006;38:S2-6.
de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016-21.
Reginster JY, Rabenda V. Adherence to anti-osteoporotic treatment: does it really matter? Future Rheumatol 2006;1:37-40.
Reginster JY. Adherence and persistence: impact on outcomes and health care resources. Bone 2006;38:S18-21.
Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310.
Reginster JY, Malaise O, Neuprez A, Jouret VE, Close P. Intermittent bisphosphonate therapy in post-menopausal osteoporosis. Progress to date. Drugs Aging 2007;6:351-9.
Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 2005;353:898-908.
Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-61.
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22.
Close P, Neuprez A, Reginster JY. Developments in the pharmacotherapeutic management of osteoporosis. Expert Opin Pharmacother 2006;7:1603-15.
Reginster JY, Spector T, Badurski J, Ortolani S, Martin TJ, Diez-Perez A et al. A short-term run-in study can significantly contribute to increasing the quality of long-term osteoporosis trials. The Strontium Ranelate Phase III Program. Osteoporos Int 2002;13:S30.
Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE et al. Risk factors for hip fracture in white women. N Engl J Med 1995;332:767-73.
Dargent-Molina P, Favier F, Grandjean H, Baudoin C, Schott AM, Hausherr E et al. Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet 1996;348:145-9.
Albrand G, Munoz F, Sornay-Rendu E, DuBoeuf F, Delmas PD. Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: The OFELY Study. Bone 2003;32:78-85.
Jensen JE, Jensen TG, Smith TK, Johnston DA, Dudrick SJ. Nutrition in orthopaedic surgery. J Bone Joint Surg Am 1982;64:1263-72.
Hannan MT, Tucker KL, Dawson-Hughes B, Cupples LA, Felson DT, Kiel DP. Effect of dietary protein on bone loss in elderly men and women: the Framingham osteoporosis study. J Bone Miner Res 2000;15:2504-12.
Wengren HJ, Munger RG, West NA, Cutler DR, Corcoran CD, Zhang J et al. Dietary protein intake and risk of osteoporotic hip fracture in elderly residents in Utah. J Bone Miner Res 2004;19:537-45.
Deprez X, Fardellone P. Nonpharmacologic prevention of osteoporotic fractures. Joint Bone Spine 2003;70:448-57.
Grisso JA, Kelsey JL, O'Brien LA, Miles CG, Sidney S. Maislin G et al. Risk factors for hip fracture in men. Hip fracture study group. Am J Epidemiol 1997;145:786-93.
Grisso JA, Kelsey JL, Strom BL, Chiu GY, Maislin G, O'Brien LA et al. Risk factors for falls as a cause of hip fracture in women. The Northeast Hip Fracture Study Group. N Engl J Med 1991;324:1326-31.
Robertson MC. Campbell AJ, Gardner MM, Devlin N. Preventing injuries in older people by preventing falls: a metaanalysis of individual-level data. J Am Geriatr Soc 2002;50:905-11.
Schwartz AV, Kelsey JL, Sidney S, Grisso JA. Characteristics of falls and risk of hip fracture in elderly men. Osteoporos Int 1998;8:240-6.
Lauritzen JB, Petersen MM, Lund B. Effect of external hip protectors on hip fractures. Lancet 1997;350:563-4.
Kannus P, Parkkari J, Niemi S, Pasanen M, Palvanen M Jaarvinen M et al. Prevention of hip fracture in elderly people with the use of a hip protector. N Engl J Med 2000;343:1506-13.
van Schoor NM, Smit JH, Twisk JW, Bouter LM, Lips P. Prevention of hip fractures by external hip protectors: a randomized controlled trial. JAMA 2003;289:1957-62.
Birks YF, Hildreth R, Campbell P, Sharpe C, Torgerson DJ, Watt I. Randomised controlled trial of hip protectors for the prevention of second hip fracture. Age Ageing 2003;32:442.